Constellation Pharmaceuticals to Present at the 38th Annual Cowen and Company Health Care Conference

CAMBRIDGE, Massachusetts, March 6, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a corporate overview at the 38th Annual Cowen and Company Health Care Conference on March 12 at 11:30 a.m. EDT. The conference is being held March 12-14 at the Marriott Copley Place in Boston, Massachusetts.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help enhance response over currently available treatment options.

For more information, please visit www.constellationpharma.com.

Contacts
W2O Group
Media contact:
Katie Engleman, +1-910-509-3977
kengleman@w2ogroup.com

or

Investor contact:
Stern Investor Relations, Inc.
Stephanie Ascher, +1-212-362-1200
stephanie@sternir.com